Read what various outlets are saying about the company
Learn about specific initiatives or opinions from members of our passionate team
Read about what we did in the past with the first iteration of this business
Industry events where Proove Genomics will be attending
Add a description about this item
Add a description about this item
Add a description about this item
Industry events where Proove Genomics will be attending
Add a description about this item
Add a description about this item
Add a description about this item
Industry events where Proove Genomics will be attending
Add a description about this item
Add a description about this item
Add a description about this item
Industry events where Proove Genomics will be attending
Add a description about this item
Add a description about this item
Add a description about this item
Files coming soon.
Confucius
By Peter Brennan, Editor
"Brian Meshkin got his day in court, and he finally feels vindicated. U.S. District Court Judge Josephine Staton of the Central District of California on December 22 threw out all federal charges against Meshkin and five others."
By Scott Schwebke, Investigator Reporter
The U.S. Attorney’s Office said in a court motion last week that it dismissed the case against Brian Javaade Meshkin, 46, “in the interests of justice.” The Ladera Ranch man, founder of Proove Biosciences Inc., was indicted in 2021 on charges of conspiracy and receiving and making illegal payments.
The dismissal follows a Dec. 11 motion seeking an evidentiary hearing filed by Meshkin’s attorney, Jason de Bretteville.
The motion alleges a government “taint team” provided at least 85 potentially privileged documents belonging to Proove to prosecutors on the trial team.
“The court was made aware of what happened and they dismissed the case,” he said in a phone interview. “The prosecution’s investigation started in 2013 and, as a result, nine people were indicted. Then the prosecution walked quietly into the night 30 days before trial.”
By Jessica Cohen, Staff Reporter
A federal judge in California has dismissed charges against the CEO of embattled genetic testing company Proove Biosciences who along with other individuals had been accused of paying physicians at least $3.5 million in kickbacks.
In a statement published Monday, Proove said, "These false allegations levied against Meshkin and Proove caused tremendous harm, as they have been widely disseminated publicly and in the media. With this dismissal, the defendants are vindicated, and this flawed investigation has been thoroughly discredited."
By Kim Delmonico
The United States government was soundly defeated and forced to ask a Federal Judge to dismiss all charges against an innovative young California company and the clinics it serves.
The judge for the United States District Court in the Central District of California has issued an order granting the United States Government’s motion to dismiss all charges in a case involving physicians and other employees from Physical Medical Associates, Ltd., National Spine and Pain Center, LLC, and Proove Biosciences, Inc.
Proove is an Irvine, California-based biosciences company that specializes in the genetic testing of pain patients. According to the company, its “proprietary effective technology” includes “genetic tests and predictive software algorithms in its CLIA-certified, CAP-accredited state-of-the-art laboratory that helped doctors objectively assess pain, predict who would misuse opioids with up to 96.7% accuracy, and provide treatment insights which resulted in 50% pain reduction within 30 days of treatment changes, saving Medicare over $70 million annually.”
By Pat Anson, Editor
The U.S. Department of Justice has quietly dropped criminal charges against the founder and CEO of Proove Biosciences, a genetic testing company based in California that was accused of paying physicians over $3.5 million in illegal kickbacks. A judge dismissed the case against Brian Meshkin and five other defendants last month “in the interests of justice” after federal prosecutors declined to move forward with the case.
“There has been so much injustice over the past 6 years that it is wonderful to see truth prevail. I am excited to have the opportunity to set the record straight and to move forward from here with my head held high,” Meshkin said in a statement.
By Alex Riggins
Jason de Bretteville, defense attorney for the lead defendant, Proove CEO Brian Meshkin, said the government attorneys never disclosed specifically why they sought a dismissal, but he speculated it was based on the case’s merits and “emerging issues relating to potential government misconduct.”
Meshkin said the decision to dismiss the case was vindication for him and his co-defendants.
“There has been so much injustice over the past (six) years that it is wonderful to see truth prevail,” Meshkin wrote in a statement he sent to the Union-Tribune. “Ultimately, the facts spoke for themselves.”
Meshkin called the investigation a “foolish” waste of millions of taxpayer dollars that resulted from “misinformation spread by a handful of disgruntled ex-employees and contractors, spread by the media, and blindly adopted by some in the Southern District of California office of the U.S. Attorney and the FBI.”
By Sherry Hseih, Healthcare Editor
Meshkin’s venture fund is a “social entrepreneurship accelerator that is helping profound social problems.” Profound Ventures plans to make seed investments in the five- to low six-digits, starting with healthcare opportunities. The current portfolio includes technologies to help people age at home.
Brian Meshkin sought a way to help doctors make better decisions in the specialty of pain management, acting on the desire in 2009 when he created Irvine-based Proove Biosciences Inc. Meshkin, Proove’s founder and chief executive, was one of five winners honored by the Business Journal at its 15th annual Excellence in Entrepreneurship Awards at a March 10 luncheon at Hotel Irvine
Brian Meshkin founded Irvine, California-based Proove Biosciences in 2009. The company developed a portfolio of tests that can determine someone’s pain profile and tolerance to different pain medications to give doctors more information before prescribing medication.
By Dina Gusovsky
Sixty percent of the score a patient receives is based on testing for genetic markets associated with addiction, of which there are several, including COMT, dopamine receptors and the opioid MU1 receptor gene.
The other 40 percent of the addiction-risk score comes from personal factors: age, personal medical history, previous substance abuse and any history of depression (due to its links to drug use).
An Irvine biotech company is hoping to take on the nation’s opioid epidemic with a genetic test it says can identify patients who are predisposed to getting addicted to painkillers.
The problem is clear: Nearly 2 million people were found to be addicted to pain medication and nearly 19,000 people died from taking pain medication in 2014, according to the American Society of Addiction Medicine.
Brian Meshkin is interviewed by Dr. Alan Beyer from Hoag Orthopedic Institute, a client of Proove Biosciences
Brian Meshkin is joined by Former Congresswoman Mary Bono and the Canada Excellence Chair of Pain Genetics Dr. Luda Diatchenko as Proove announces important data at the AAPM meeting in 2018
Brian Meshkin is selected by the OCTANe/OC Tech Alliance as the CEO of the Year of an Emerging Technology Company
Brian Meshkin speaks at Medical Device Events Conference in 2019
U.S. Government Dismisses Case Against Proove Biosciences Founder and CEO Brian Meshkin. False Charges Spread by STAT News Discarded. Dismissal Issued as Leading Experts, Researchers, and Former Government Officials Prepared to Testify in Defense of Proove and Meshkin.
Researchers from the University of Southern California, Interventional Pain Institute, and Proove Biosciences Publish Clinical Utility Study Supporting Precision Medicine in Pain Perception
World Leader in Precision Medicine Testing Incorporates Evidence-Based, Expert-Substantiated Clinical Phenotypes to Its Algorithm to Better Understand Patient Pain Sensitivity
Proove Launches the Only Commercially Available Genetic Analysis Offering Personalized Medical Treatment Recommendations for TMD Sufferers and Insights Into Contributing Causes of Orofacial Pain
Listed on Deloitte Technology Fast500 - Attributes 1,386 Percent Revenue Growth to Successful Patented Precision Medicine Platform Designed to Improve Outcomes for Patients, Providers and Insurers
Listed on Deloitte Technology Fast500 - Attributes 1,386 Percent Revenue Growth to Successful Patented Precision Medicine Platform Designed to Improve Outcomes for Patients, Providers and Insurers
Read about Proove's tremendous accomplishments from mid-2016 until early 2017
Read about Proove's tremendous accomplishments from 2013 until the summer of 2016
Copyright © 2023 Proove Genomics - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.